PDCD1 and neoplasm: Another study showed that anti-TIGIT prevented NK cell exhaustion and improved its immunogenicity in mouse models, resulting in tumor-specific T cell immunity and magnifying effects of combination immunotherapy with PD-1 and PD-L1 [141].